Navigation Links
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
Date:3/24/2011

AUSTIN, Texas, March 24, 2011 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer.  OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service. 

"The use of biomarker tools throughout drug development is a requirement for researchers who must balance leaner R&D budgets with the greater demands for safety, innovation and success," said Craig Benson, RBM president and chief executive officer. "From one drop of serum, OncologyMAP® can deliver data that could help solve therapeutic and diagnostic dilemmas related to cancer making this biomarker panel an essential component of the development toolkit."

OncologyMAP® provides drug researchers with an accurate and affordable means of evaluating the efficacy and safety of therapeutic candidates. The test is validated to clinical laboratory standards enabling biomarker pattern discoveries made in basic research to be reproducibly extended into clinical trials. The use of sensitive, reproducible biomarker patterns as objective measures of drug efficacy and toxicity can accelerate development efforts and facilitate decision-making to avoid costs associated with late-stage drug attrition.

OncologyMAP® is based on RBM's proprietary Multi-Analyte Profiling (M
'/>"/>

SOURCE Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
2. Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
3. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
4. China Medicine Announces Strong Second Quarter 2008 Results
5. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
6. As personalized, genomic medicine takes off, four developing countries show the way for others
7. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
8. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
9. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
10. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
11. Dr. Larry Corey Named New Member of the Institutes of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Demanding industrial and ... engineered of synthetic Sapphire and Glass Ball Lenses, now ... Swiss Jewel Company , of Philadelphia , PA. ... and collimating the light beams without the need for ... and natural durability (9 mohs) make it the ideal ...
(Date:6/18/2013)... 18, 2013 RegeneCure announced ...  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a ... A common problem encountered when patients have a tooth replaced ... volume to house the implant. Consequently there is often a ... the natural bone regenerates. The bone substitute material, in turn, ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... June 18, 2013 This webinar ... pharmaceutical advertising and promotion, and review the basic ... learn how to apply these principles through real ... ,     The fundamentals on FDA regulations and ... labeling ,     Assessing traditional and newer forms ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Novocell, Inc. , a preclinical stage diabetes ... award totaling $20 million from the California Institute for Regenerative ... scientists at the University of California, San Francisco (UCSF), led ... million. The funding will advance Novocell,s development of a first ...
... Nev., Oct. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: ... a $300 million securitization transaction intended to monetize certain ... closing of the transaction, which is expected to occur ... QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary ...
... Novavax, Inc. (Nasdaq: NVAX ) announced ... joint venture between Cadila Pharmaceuticals in India, has ... will be used to produce pandemic and seasonal ... virus-like particle (VLP) vaccine technology to produce commercial-scale ...
Cached Biology Technology:Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 5
(Date:6/18/2013)... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ... the ten largest recorded. That would range from an ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... sites of fundamental geodynamic, geochemical and biological processes and ... for us. Scientific marine drilling and coring is crucial ... (sub-) seafloors to advance our knowledge in the Earth ... (ESF) European Collaborative Research (EUROCORES) programme EuroMARC is an ...
... Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. ... Nature Medicine that supports the broad ... antibody platform, showing that its PS-targeting drug bavituximab ... models. Bavituximab is in clinical ...
... Futronic Technology Company Limited, a,global provider of ... of FS22, a high performance fingerprint access and,attendance ... launched,FS21M (mid-range device) and FS20 (low cost device), ... and attendance control device.,FS22 uses a powerful Digital ...
Cached Biology News:Europe cores in EUROCORES: Ocean drilling in EuroMARC 2Europe cores in EUROCORES: Ocean drilling in EuroMARC 3Europe cores in EUROCORES: Ocean drilling in EuroMARC 4Europe cores in EUROCORES: Ocean drilling in EuroMARC 5Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Futronic Launches FS22 Fingerprint Access Control Device 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
Biology Products: